AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and as of August 2023 is in Phase I clinical trials for the treatment of solid tumors. It was created to target a specific variant of PCNA found only in ...
Of note, we also observed enhanced activity when AOH is combined with VEN. While VEN is FDA-approved for AML, AOH is a novel compound currently in clinical trials for solid tumors and undergoing IND-enabling studies for leukemia.Data availability No datasets were generated or analysed during ...